Nonlinear intestinal absorption kinetics of cefuroxime axetil in rats

被引:20
作者
RuizBalaguer, N [1 ]
Nacher, A [1 ]
Casabo, VG [1 ]
Merino, M [1 ]
机构
[1] UNIV VALENCIA, FAC PHARM, DEPT PHARMACEUT, BURJASSOT 46100, SPAIN
关键词
D O I
10.1128/AAC.41.2.445
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Cefuroxime is commercially available for parenteral administration as a sodium salt and for oral administration as cefuroxime axetil, the 1-(acetoxy)ethyl ester of the drug, Cefuroxime axetil is a prodrug of cefuroxime and has little, if any, antibacterial activity until hydrolyzed in vivo to cefuroxime, In this study, the absorption of cefuroxime axetil in the small intestines of anesthetized rats was investigated in situ, by perfusion at four concentrations (11.8, 59, 118, and 200 mu M) Oral absorption of cefuroxime axetil can apparently be described as a specialized transport mechanism which obeys Michaelis-Menten kinetics, Parameters characterizing absorption of prodrug in free solution were obtained: maximum rate of absorption (V-max) = 289.08 +/- 46.26 mu M h(-1), and K-m = 162.77 +/- 31.17 mu M. Cefuroxime axetil transport was significantly reduced in the presence of the enzymatic inhibitor sodium azide. On the other hand, the prodrug was metabolized in the gut wall through contact with membrane-bound enzymes in the brush border membrane before absorption occurred. This process reduces the prodrug fraction directly available for absorption, From a bioavailability point of view, therefore, the effects mentioned above can explain the variable and poor bioavailability following oral administration of cefuroxime axetil. Thus, future strategies in oral cefuroxime axetil absorption should focus on increasing the stability of the prodrug in the intestine by modifying the prodrug structure and/or targeting the compound to the absorption site.
引用
收藏
页码:445 / 448
页数:4
相关论文
共 26 条
[11]  
GARRIGUES TM, 1991, EUR J CLIN PHARMACOL, V41, P179
[12]  
GEROLD LM, 1992, PHARM RES-DORDR, V9, P687
[13]  
Harding S.M, 1990, RES CLIN FORUMS, V12, P23
[14]   PRECISION, ACCURACY, AND DATA ACCEPTANCE CRITERIA IN BIOPHARMACEUTICAL ANALYSIS [J].
KARNES, HT ;
MARCH, C .
PHARMACEUTICAL RESEARCH, 1993, 10 (10) :1420-1426
[15]  
KEES F, 1991, ARZNEIMITTEL-FORSCH, V41-2, P843
[16]   STUDIES ON THE RELIABILITY OF A BIHYPERBOLIC FUNCTIONAL ABSORPTION-MODEL .1. RING-SUBSTITUTED ANILINES [J].
MARTINVILLODRE, A ;
PLADELFINA, JM ;
MORENO, J ;
PEREZBUENDIA, D ;
MIRALLES, J ;
COLLADO, EF ;
SANCHEZMOYANO, E ;
DELPOZO, A .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1986, 14 (06) :615-633
[17]  
McEvoy GK, 1994, AHFS DRUG INFORMATIO, P152
[18]   EVIDENCE OF A SPECIALIZED TRANSPORT MECHANISM FOR THE INTESTINAL-ABSORPTION OF BACLOFEN [J].
MERINO, M ;
PERISRIBERA, JE ;
TORRESMOLINA, F ;
SANCHEZPICO, A ;
GARCIACARBONELL, MC ;
CASABO, VG ;
MARTINVILLODRE, A ;
PLADELFINA, JM .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1989, 10 (03) :279-297
[19]   PHARMACOKINETICS OF CEFUROXIME AXETIL SUSPENSION IN INFANTS AND CHILDREN [J].
POWELL, DA ;
JAMES, NC ;
OSSI, MJ ;
NAHATA, MC ;
DONN, KH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (10) :2042-2045
[20]  
RIBERA JP, 1986, CIENC IND FARM, V5, P282